COH.AX stock plunges 40.7% as Cochlear cuts profit guidance

Cochlear Limited’s COH.AX stock has become one of the ASX’s biggest losers in pre-market trading, with shares down 40.7% to A$99.58 after the hearing implant maker slashed full-year profit guidance. The Sydney-based medical device company, which employs nearly 50,000 people globally, triggered a sharp selloff when it announced lower earnings expectations. This marks a dramatic reversal for COH.AX stock, which traded at A$319.56 just 12 months ago. The healthcare sector weakness reflects broader market concerns about the company’s growth trajectory and profitability outlook.

COH.AX Stock Price Collapse and Market Reaction

COH.AX stock crashed A$68.36 in a single session, representing the steepest one-day decline in years. The stock opened at A$113.88 but fell to a low of A$97.88, wiping out billions in market value. Trading volume surged to 4.79 million shares, more than 14 times the average daily volume of 327,956 shares. This exceptional volume confirms institutional and retail investors are exiting positions rapidly. Cochlear hit a decade low after slashing profit guidance, signaling serious operational challenges ahead. The stock now trades below its 50-day moving average of A$180.87 and 200-day average of A$258.08.

Earnings Guidance Cut Triggers Investor Panic

Cochlear’s decision to cut full-year earnings guidance shocked the market and sparked immediate selling pressure. The company’s earnings per share (EPS) stands at 5.27, but forward guidance suggests lower profitability ahead. The price-to-earnings ratio has compressed to 18.9x, down from historical levels above 30x, yet investors remain skeptical about valuation support. Management’s guidance cut indicates demand weakness in key markets or margin compression from rising costs. The company faces headwinds in its core cochlear implant business, which generates the majority of revenue. With earnings announcement scheduled for August 13, 2026, investors will scrutinize every detail of operational performance and management commentary.

Technical Indicators Show Severe Oversold Conditions

Technical analysis reveals COH.AX stock has entered deeply oversold territory. The Relative Strength Index (RSI) sits at 38.34, below the 40 level that signals extreme selling pressure. The Commodity Channel Index (CCI) reads -118.41, indicating oversold conditions rarely seen in normal market environments. Williams %R stands at -82.34, another oversold signal. However, oversold conditions don’t guarantee immediate recovery. The stock trades below both Bollinger Bands middle line (A$170.13) and lower band (A$162.37), suggesting downside momentum remains intact. Volume-weighted indicators like the Money Flow Index (MFI) at 37.44 confirm institutional liquidation is ongoing.

Valuation Metrics and Financial Health Assessment

Despite the crash, COH.AX stock valuation metrics reveal mixed signals. The price-to-book ratio of 5.67x remains elevated compared to the healthcare sector average of 4.21x. Free cash flow yield stands at just 1.83%, while the dividend yield is 1.28% with a payout ratio of 81.5%. The company maintains a strong balance sheet with debt-to-equity of 0.22x and current ratio of 2.46x, indicating adequate liquidity. However, the enterprise value-to-EBITDA multiple of 19.79x suggests the market priced in significant growth that may not materialize. Track COH.AX on Meyka for real-time updates on valuation changes and analyst sentiment shifts.

Market Sentiment and Trading Activity

Trading Activity: The exceptional volume spike to 4.79 million shares reflects panic selling across all investor categories. Institutional funds are likely rebalancing portfolios away from healthcare exposure. Retail investors who bought near the A$319 peak are facing substantial losses. The stock’s movement from day high (A$114.95) to day low (A$97.88) shows intraday volatility exceeding A$17, creating whipsaw conditions for traders.

Liquidation Pressure: The negative on-balance volume (OBV) of -2.19 million confirms sustained selling pressure without offsetting buying interest. The MACD histogram at 1.28 shows momentum is negative, with the signal line at -5.65 well below the MACD at -4.37. This technical deterioration suggests further downside risk before stabilization occurs.

Meyka AI Grade and Price Forecast Analysis

Meyka AI rates COH.AX stock with a grade of B+, suggesting a neutral-to-buy stance despite recent weakness. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects the company’s strong fundamentals offset by near-term headwinds. Meyka AI’s forecast model projects COH.AX stock reaching A$296.47 within 12 months, implying 197% upside from current levels. The three-year forecast stands at A$314.77, while the five-year target is A$333.14. These forecasts assume the company stabilizes operations and returns to growth. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

COH.AX stock has entered a critical phase following the profit guidance cut and subsequent 40.7% crash. The hearing implant maker now trades at decade lows, creating both risk and opportunity for different investor profiles. Fundamental metrics remain solid with strong cash generation and low leverage, but near-term sentiment is decidedly negative. The technical setup shows extreme oversold conditions, yet momentum indicators suggest selling pressure persists. Investors should monitor the August earnings announcement closely for management commentary on market recovery timelines. The stock’s valuation has compressed significantly, but patience may be required before a sustainable recovery emerges. Risk-tolerant investors might view current levels as accumulation opportunities, while conservative investors should wait for stabilization signals before re-entering positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.